D. Boral Capital Reiterates Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)
D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics […]
D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics […]
